Picture

Panavance @panavance

We are a clinical-stage pharmaceutical company focused on improving the outcomes and lives of cancer patients. panavance.com Joined October 2021
  • Tweets
    161
  • Followers
    2K
  • Following
    53
  • Likes
    5
panavance Profile Picture

Panavance @panavance

2 days ago

Panavance is focused on developing misetionamide (GP-2250) in #pancreaticcancer and #ovariancancer. Upon conclusion of our Phase 1 clinical study, we plan to move into two randomized studies in platinum-resistant ovarian cancer and pancreatic cancer. For more information, visit…

panavance Profile Picture

Panavance @panavance

2 weeks ago

There were an estimated 20,000 new cases of #ovariancancer diagnosed in the US in 2023. With National Ovarian Cancer Awareness month approaching in May, we wanted to share Panavance’s mission in advancing these treatments. We are currently planning a Phase 1/2 study in platinum…

panavance Profile Picture

Panavance @panavance

3 weeks ago

Our lead therapeutic, misetionamide (GP-2250) is being evaluated in a Phase 1 study to investigate the safety, tolerability, and preliminary antitumor activity in combination with standard of care treatment for patients with #pancreatic cancer. Our clinical trial sites include:…

panavance Profile Picture

Panavance @panavance

3 weeks ago

At Panavance, we’re focused on advancing cancer treatment with a unique and novel mechanism of action. Our misetionamide (GP-2250) targets cancer cell metabolism by disrupting cancer cell energy pathways restricting growth and proliferation. Explore the science behind…

panavance Profile Picture

Panavance @panavance

4 weeks ago

What sets misetionamide (GP-2250) apart? Misetionamide is a highly selective yet broadly active cancer therapeutic with 22 publications and abstracts over 9+ years of preclinical and clinical research. By targeting the energy metabolism of cancer cells, it has been shown to…

panavance Profile Picture

Panavance @panavance

a month ago

Based on statistically significant pre-clinical results, we are planning a clinical trial of misetionamide (GP-2250) in #ovariancancer with a pre-IND meeting expected later this year. For updates visit: panavance.com/gp-2250-pipeli…

panavance Profile Picture

Panavance @panavance

2 months ago

Did you know that #OvarianCancer is the 5th leading cause of female cancer? Panavance is planning a Phase 1b/2 study in platinum resistant ovarian cancer later this year. Check out this abstract from last year’s AACR conference here: panavance.com/wp-content/upl… and be sure to…

panavance Profile Picture

Panavance @panavance

2 months ago

Last week CEO Greg Bosch attended the BIO CEO & Investor Conference to present the Panavance story and meet with investors and partners. Greg presented the opportunity for misetionamide (GP-2250) in development for the treatment of #ovariancancer and #pancreaticcancer. For more…

panavance Profile Picture

Panavance @panavance

2 months ago

Panavance has active studies in both preclinical and clinical phases, with a primary focus on pancreatic and ovarian cancers. We are also exploring the full potential of misetionamide (GP-2250) in additional oncology indications as we advance our research activities. Stay…

panavance Profile Picture

Panavance @panavance

2 months ago

Greg Bosch, our Chairman and CEO will be presenting on Tuesday, February 27 at #BIOCEO24 in New York, NY from 10:15 a.m. – 10:30 a.m. He will be presenting Panavance’s story and our lead therapeutic, misetionamide (GP-2250) for the treatment of #pancreaticcancer and…

panavance Profile Picture

Panavance @panavance

2 months ago

February is #nationalcancerpreventionmonth. Panavance is dedicated to fostering awareness, supporting research, and encouraging early detection and prevention. Learn more about misetionamide (GP-2250) and its potential to make a meaningful impact across diverse oncological…

panavance Profile Picture

Panavance @panavance

3 months ago

Panavance is focused on making strides in cancer treatment by addressing the unmet needs of patients. We are currently recruiting for our Phase 1 trial in pancreatic cancer for our lead therapeutic, misetionamide (GP-2250). It has demonstrated high tumor cell selectivity and…

panavance Profile Picture

Panavance @panavance

3 months ago

Panavance is pleased to announce another scientific publication in the peer-reviewed journal, Anti-Cancer Drugs, entitled, “Antineoplastic Activity of GP-2250 In Vitro and in Mouse Xenograft Models.” Misetionamide (GP-2250) showed broad antineoplastic activity in 8 different…

panavance Profile Picture

Panavance @panavance

3 months ago

Today is #worldcancerday! This year’s theme is to eliminate health inequities by addressing their root causes, ensuring that everyone has access to quality health services when, where, and how they need them. Learn more at worldcancerday.org/about/2022-202…

panavance Profile Picture

Panavance @panavance

3 months ago

Panavance is pleased to announce another scientific publication in the peer-reviewed journal, Anti-Cancer Drugs, entitled, “Antineoplastic Activity of GP-2250 In Vitro and in Mouse Xenograft Models.” Misetionamide (GP-2250) showed broad antineoplastic activity in 15 different…

panavance Profile Picture

Panavance @panavance

3 months ago

January is Pancreatic Cancer Clinical Trial Awareness Month #CTAM! Clinical trials are pivotal in advancing treatment options for this complex disease. Misetionamide (GP-2250) is in Phase 1 development for #pancreatic cancer and now includes an additional #clinicaltrial site in…

panavance Profile Picture

Panavance @panavance

3 months ago

Panavance is dedicated to addressing #cancer types that are difficult to treat with a clear unmet need. Our lead therapeutic, misetionamide (GP-2250) is now in a Phase 1 trial to investigate the safety, tolerability, and preliminary antitumor activity in combination with…

panavance Profile Picture

Panavance @panavance

4 months ago

Panavance was honored to partner with @letswinpc for their 6th annual benefit, committed to providing resources, raising awareness, and finding the best treatment options for pancreatic cancer patients and their caregivers. Panavance continues its dedication to combating…

Trends for United States

Anthony Taylor
2.921 posts
Klopp
80,8 B posts
#WHULIV
24 B posts
#Caturday
8.022 posts
#SaturdayMorning
4.625 posts
#SaturdayVibes
7.587 posts
Good Saturday
26,3 B posts
West Ham
11 B posts
Barr
64,2 B posts
Gakpo
8.769 posts
$FISH
28,7 B posts
Howard Stern
109 B posts
Areola
3.410 posts
Happy Birthday Kirby
8.950 posts
Gravenberch
3.406 posts
Bowen
10,8 B posts
Robbo
3.700 posts
Amad
5.790 posts
SAROCHA REBECCA IN MANILA
312 B posts
Tripp

You might like

Adamas One Corp, The Original Lab-Grown Diamond Company, is a high-quality diamond manufacturer based in the United States. (NASDAQ: $JEWL)
Adamas One Corp
@AdamasOneCorp
1K Followers
LOWENCO is a leading manufacturer of best in class sustainable ultra-low temperature (ULT) storage solutions for the pharma and biotech industries. ❄️🌱♻️
LOWENCO
@LOWENCO
4K Followers
AI for Wealth Our holdings: @TIFIN_Wealth • @DiscoverMagnifi • @TIFINGive • @TIFIN_AtWork • @Sage_CIO • @Helix_HL
TIFIN
@TIFINfintech
3K Followers
The leading MDR provider trusted by some of the world’s most renowned brands to expel adversaries, minimize risk, & build security resilience. https://t.co/uTjUcRDveB
Expel
@ExpelSecurity
13K Followers
iTolerance is a privately held regenerative medicine company enabling tissue, organoid or cell therapy without the need for life-long immunosuppression.
iTolerance
@iTolerance_inc
3K Followers
@SADA's podcast for business leaders and technology enthusiasts exploring how @GoogleCloud is transforming the industry. Check it out: https://t.co/blgjbQaUyW
Cloud N Clear
@cloudnclear
8K Followers
The app for #CBRS #PLTE 📲 The Internet of Workers #IoW platform for all field comms & workforce management
weavix
@weavixiow
4K Followers
Matinas BioPharma ( $MTNB ) is focused on improving the intracellular delivery of nucleic acids and small molecules with its LNC platform technology.
Matinas BioPharma
@MatinasBio
10K Followers
Moleculin (NASDAQ: $MBRX) is a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant cancers and viruses.
Moleculin Biotech
@moleculinbio
5K Followers
Rooted in science. Obsessed with quality. We put the health of your family first.
ViaCord
@ViaCord
12K Followers
A community of options and futures traders. Education, mentorship, & wisdom. Where iron sharpens iron. Disclaimer: https://t.co/HNllvWbwl0
Independent Traders G..
@IndieTraders
4K Followers
An adaptive energy services company that manages assets and power to optimize the delivery of clean, affordable and reliable power for its network of customers.
Sunnova
@SunnovaEnergy
16K Followers
Trade and monitor your #futures & #options account with Ironbeam App. Take your trading on the go with a powerful trading platform.
Ironbeam App
@IronbeamApp
2K Followers
At TheSaleMark, you will find the latest #Sales trend, Sales strategies, and Cutting-edge solutions to achieve your sales goal.
TheSalesMark
@TheSalesMark
3K Followers
Late-stage #biopharma company advancing therapies for acute and chronic #gastrointestinal (#GI) complications
Palisade Bio
@PalisadeBio
2K Followers